We continually monitor RED BOOK® Average Wholesale Price (AWP) of the most common drugs seen in Workers’ Compensation Medicare Set-Aides (WCMSA) in order to identify pricing changes affecting MSAs positively. The month of August brought price drops for the medications quetiapine (Seroquel®), in multiple strengths, commonly prescribed to treat bi-polar disorder and lansoprazole (Prevacid®) 30mg a Proton-Pump Inhibitor, used to treat stomach ulcers, gastro esophageal reflux disease (GERD) and high levels of stomach acid.
Below are the products Optum identified with a reduced AWP and confirmed in the Centers for Medicare and Medicaid Services (CMS) WCMSA portal.
|Product Name||NDC Code||Dosage Form||Strength||AWP Unit Price Reduction|
|Quetiapine Fumarate||00904-6638-61||TAB||25 mg||$0.04|
|Quetiapine Fumarate||00310-8280-60||TER||50 mg||$8.01|
|Quetiapine Fumarate||00310-8281-60||TER||150 mg||$14.98|
|Quetiapine Fumarate||00310-8282-60||TER||200 mg||$16.46|
|Quetiapine Fumarate||00310-8283-60||TER||300 mg||$21.75|
|Quetiapine Fumarate||00310-8284-60||TER||400 mg||$25.63|
Please note that RED BOOK AWP is subject to change and this pricing is subject to an increase or decrease in the future.
CMS will utilize the lowest AWP when reviewing a WCMSA, therefore the lower pricing of these medications will immediately impact the prescription costs for WCMSAs (both present as well as prior WCMSA’s that have not settled and there is no CMS determination issued) where these drugs are prescribed.
It is our recommendation that carriers, TPAs and claim handlers review cases where the above noted medications are prescribed to determine the benefit from decreased cost. We will proactively reach out to our clients in reference to previously completed WCMSA’s where these medications were prescribed.
Another change occurring is the generic availability of Relpax® tablets (eletriptan hbr tablets) in 20mg and 40mg. This new generic offers an 11 percent decrease in AWP price. As more manufacturers bring generics for Relpax to market, we expect the price to decrease even more over the next year.
We previously identified pricing changes for several other drugs recently, such as carisoprodol, aripiprazole and esomeprale providing significant MSA savings for clients on cases not settled or approved by CMS. We will continue to monitor future AWP changes and generic equivalents introduced to the market and will keep the industry informed.